Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients

• Status: Completed
• Trial end date: 2017-10-12
• Target enrollment: 0
• Participant gender: All

Summary

The specific research questions addressed in the present study are:

• to investigate the impact of treatment with low-dose aspirin in HIV-1-infected patients treated with ABC and test it would result in decreased in vivo platelet activation and platelet hyperreactivity

• to investigate if aspirin has the same effects in HIV-infected as in HIV-uninfected patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Azienda Ospedaliera di Perugia
• Treatments: Abacavir; Aspirin

Criteria

Inclusion Criteria:

• a viral load <50 copies per millilitre

• ABC treatment for at least 6 months

Exclusion Criteria:

• age younger than 18

• nonsteroidal anti-inflammatory drug use in the past week (including aspirin), renal failure (creatinine clearance <30 mL/min), platelet count <100,000/microL, history of gastrointestinal bleeding within the last 6 months, presence of coexisting inflammatory disease, cancer, active bacterial or fungal infection, bleeding history, oral anticoagulant therapy and allergy to aspirin